CALCA and migraine disorder: Two classes of CGRP(-receptor) targeting medication have been developed, i.e. the small molecule CGRP receptor antagonists (gepants) and the monoclonal antibodies targeting CGRP (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab), and both have been shown to be effective in the treatment of migraine [5, 6].